Търсене на изпитвания

Активни:

Намерени 3,079 изпитвания Стр. 113 от 154

Активно (без набиране) Фаза 3

DOR/ISL in HIV-1 Antiretroviral Treatment-naïve Participants (MK-8591A-053)

HIV-1 Infection

This is a randomized, active-controlled, double-blind clinical study designed to evaluate the antiretroviral activity, safety, and tolerability of doravirine/islatravir (DOR/ISL \[MK-8591A\]) in treatment-naïve participants with human immunodeficiency virus type 1 (HIV-1) infection. It is hypothesized that DOR/ISL is non-inferior to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) as assessed by the percentage of participants with HIV-1 ribonucleic acid (RNA) \

Начало: 08.03.2023 Край: 05.08.2029 Възраст: от 18 г. Лечение

Argentina, Canada, Chile +18 Merck Sharp & Dohme LLC NCT05705349

Активно (без набиране) Фаза 2

A Study Evaluating Daily Oral Doses of TLC-3595 in Participants With Insulin Resistance

Insulin Resistance

This Phase 2a study is designed to evaluate the safety, tolerability, effectiveness, and pharmacokinetics (PK) of TLC-3595 in subjects with insulin resistance.

Начало: 08.03.2023 Край: 01.12.2024 Възраст: 18–70 г. Лечение

New Zealand OrsoBio, Inc NCT05665751

Активно (без набиране) Фаза 1

Honeycomb: Evaluation of Radiprodil in Children with GRIN-related Disorder

GRIN-related Disorders

Study RAD-GRIN-101 is a phase 1B trial to assess safety, tolerability, PK, and potential efficacy of radiprodil for the treatment of GRIN-related disorder in children with a Gain-of-Function (GoF) genetic variant. The study is open-label, so all participants will be treated with radiprodil. Subjects' participation in the study is expected to last up to six months in Part A. After the end of part A, all participants who are still eligible can choose to continue to receive radiprodil as part of an open-label long-term treatment period (Part B).

Начало: 07.03.2023 Край: 01.11.2026 Възраст: 6–12 г. Лечение

Australia, Canada, Germany +5 GRIN Therapeutics, Inc. NCT05818943

Активно (без набиране) Фаза 2

A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer Metastatic Non-small Cell Lung Cancer

The purpose of this study is to assess the antitumor activity, safety, and tolerability of tislelizumab plus investigational agent(s) with or without chemotherapy. This study is structured as a master protocol with separate sub- studies. Sub-study 1 includes participants with non-small cell lung cancer (NSCLC) with high programmed cell death protein ligand-1 (PD-L1) expression (≥ 50%), and Sub-study 2 includes participants with NSCLC with low or negative (PD-L1) expression (\< 50%).

Начало: 07.03.2023 Край: 01.10.2026 Възраст: от 18 г. Лечение

Australia, Brazil, Canada +12 BeiGene NCT05635708

Активно (без набиране) Фаза 3

Long-term Efficacy and Safety of Tozorakimab in Participants With Chronic Obstructive Pulmonary Disease With a History of Exacerbations (PROSPERO).

Chronic Obstructive Pulmonary Disease (COPD)

Subjects who completed either OBERON or TITANIA will be offered the opportunity to consent for this Multicentre, Double-blind, Randomised, Placebo controlled, Parallel Group, Phase 3, extension study to evaluate the safety and efficacy of Tozorakimab in adult participants with symptomatic COPD.

Начало: 06.03.2023 Край: 28.05.2026 Възраст: 40–130 г. Лечение

Argentina, Australia, Belgium +32 AstraZeneca NCT05742802

Активно (без набиране) Фаза 3

A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma

Melanoma

The purpose of this study is to demonstrate that the study drug exposure level of the nivolumab + relatlimab FDC subcutaneous (SC) formulation is not worse than nivolumab + relatlimab FDC intravenous (IV) administration in participants with previously untreated metastatic or unresectable melanoma.

Начало: 06.03.2023 Край: 18.11.2027 Възраст: от 12 г. Лечение

Australia, Belgium, Brazil +14 Bristol-Myers Squibb NCT05625399

Активно (без набиране) Фаза 3

A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer

Advanced Breast Cancer

A study to learn about a new medicine called ARV-471 (PF-07850327) in people who have advanced metastatic breast cancer.

Начало: 03.03.2023 Край: 15.05.2028 Възраст: от 18 г. Лечение

Argentina, Australia, Belgium +26 Pfizer NCT05654623

Активно (без набиране)

Exercise and Cardiac Stunning During HD

End-stage Kidney Disease Hemodialysis

The purpose of this study is to determine the effect of a 12-week cycling during hemodialysis program on hemodialysis-induced myocardial stunning in adult individuals receiving hemodialysis.

Начало: 01.03.2023 Край: 01.03.2026 Възраст: от 18 г. Лечение

Australia, Canada University of Manitoba NCT04877041

Активно (без набиране) Фаза 3

REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels

Cardiovascular Disease

This study will look at the effects of CagriSema on cardiovascular events (for example heart attack and stroke) in people living with cardiovascular disease. Participants will either get CagriSema or a dummy medicine (also called "placebo") which has no effect on the body. Which treatment participants will get will be decided by chance. Participant's chance of getting CagriSema or placebo is the same. Participants will inject the study medicine once a week. The study medicine will be injected briefly with a thin needle, typically in the stomach, thighs or upper arms. The study will last for up to 4.5 years.

Начало: 01.03.2023 Край: 13.10.2027 Възраст: от 55 г. Лечение

Argentina, Australia, Brazil +21 Novo Nordisk A/S NCT05669755

Активно (без набиране) Фаза 3

COVID-19 Booster Study in Healthy Adults in Australia

COVID-19

This is a double-blinded, randomised study to determine the safety, reactogenicity, and immunogenicity of a bivalent mRNA Moderna COVID-19 vaccine or a protein-based Novavax COVID-19 vaccine given as a fourth dose in healthy adults in Australia.

Начало: 28.02.2023 Край: 01.04.2026 Възраст: от 18 г. Превенция

Australia Murdoch Childrens Research Institute NCT05658523

Активно (без набиране) Фаза 1/2

An Open-label, Study to Assess Safety, Efficacy and Cellular Kinetics of YTB323 in Severe, Refractory Systemic Lupus Erythematosus

Systemic Lupus Erythematosus Lupus Nephritis

The study is intended to assess safety, efficacy and cellular kinetics of YTB323 treatment in participants with severe refractory systemic lupus erythematosus.

Начало: 28.02.2023 Край: 09.09.2026 Възраст: 18–65 г. Лечение

Australia, France, Germany +2 Novartis Pharmaceuticals NCT05798117

Активно (без набиране) Фаза 1

A Study of Tolinapant in Combination With Oral Decitabine/Cedazuridine and Oral Decitabine/Cedazuridine Alone in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma (R/R PTCL)

Relapsed/Refractory Peripheral T-cell Lymphoma

The primary purpose of the study is to assess safety, and to identify the recommended phase 2 dose (RP2D) of tolinapant in combination with oral decitabine/cedazuridine in Phase 1 and to assess preliminary efficacy as determined by overall response rate (ORR) in Phase 2. As no safe and tolerable dosing for the combination of tolinapant and decitabine/cedazuridine was identified based on protocol defined criteria, Sponsor decided to halt recruitment and to not conduct Phase 2 of the study.

Начало: 22.02.2023 Край: 31.03.2026 Възраст: от 18 г. Лечение

Australia, France, Italy +4 Taiho Oncology, Inc. NCT05403450

Активно (без набиране) Фаза 3

Safety and Efficacy Study of Viaskin Peanut in Peanut-allergic Children 4-7 Years of Age

Allergy, Peanut

The primary purpose of this study is to assess the efficacy and safety of daily DBV712 250 micrograms (mcg) to induce desensitization to peanut in peanut-allergic children 4-7 years of age over a 12-month double-blind, placebo-controlled (DBPC) Treatment Period.

Начало: 21.02.2023 Край: 01.10.2029 Възраст: 4–7 г. Лечение

Australia, Canada, France +6 DBV Technologies NCT05741476

Активно (без набиране) Фаза 2

Study With Various Immunotherapy Treatments in Participants With Lung Cancer

Advanced Non-Small Cell Lung Cancer

The purpose of this study is to assess the objective response rate (ORR) of immunotherapy-based combination therapy and to assess the safety and tolerability of immunotherapy-based combination therapy.

Начало: 21.02.2023 Край: 01.12.2027 Възраст: от 18 г. Лечение

Australia, France, Georgia +7 Gilead Sciences NCT05676931

Активно (без набиране)

Technology Assisted Cognitive Behavioural Therapy Intervention for Anxiety in People Living With Cognitive Impairment

Dementia Cognitive Impairment Anxiety

This study is a randomized controlled trial (RCT) of a remotely-delivered, technology-assisted psychotherapy program, supported by an innovative software platform for people with cognitive impairment experiencing anxiety.

Начало: 20.02.2023 Край: 15.04.2026 Възраст: от 18 г. Лечение

Australia The University of Queensland NCT05528302

Активно (без набиране) Фаза 3

A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Antiretroviral Therapy (ART) (MK-8591A-051)

HIV-1 Infection

The primary objectives of this study are to evaluate the safety and tolerability of a switch to Doravirine/Islatravir (DOR/ISL) compared with continued baseline antiretroviral therapy (ART), through Week 48; and to evaluate the antiretroviral activity of a switch to DOR/ISL compared with continued baseline ART at Week 48. The primary hypothesis is that DOR/ISL is non-inferior to continued baseline ART, as assessed by the percentage of participants with HIV-1 ribonucleic acid (RNA) ≥50 copies/mL at Week 48, with a margin of 4 percentage points used to define non-inferiority.

Начало: 20.02.2023 Край: 11.07.2028 Възраст: от 18 г. Лечение

Australia, Canada, Colombia +5 Merck Sharp & Dohme LLC NCT05631093

Активно (без набиране) Фаза 3

A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-052)

HIV-1 Infection

The primary objectives of this study are to evaluate the antiretroviral activity of a switch to Doravirine/Islatravir (DOR/ISL) compared with continued Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) at Week 48; and to evaluate the safety and tolerability of a switch to DOR/ISL compared with continued BIC/FTC/TAF, through Week 48. The primary hypotheses are that (1) DOR/ISL is non-inferior to continued BIC/FTC/TAF, as assessed by the percentage of participants with HIV-1 ribonucleic acid (RNA) ≥50 copies/mL at Week 48, with a margin of 4 percentage points used to define non-inferiority; and (2) DOR/ISL is superior to BIC/FTC/TAF, as assessed by the percentage of participants with HIV-1 RNA ≥50 copies/mL at Week 48.

Начало: 17.02.2023 Край: 04.08.2028 Възраст: от 18 г. Лечение

Australia, Chile, Israel +3 Merck Sharp & Dohme LLC NCT05630755

Активно (без набиране) Фаза 1

A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to

Respiratory Syncytial Virus Human Metapneumovirus

The purpose of this study is to assess the safety and immunogenicity of mRNA-1365, an mRNA vaccine targeting respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) and mRNA-1345, an mRNA vaccine targeting RSV, in participants aged 5 months to \

Начало: 15.02.2023 Край: 30.09.2026 Възраст: 5–24 г. Лечение

Australia, Canada, Panama +3 ModernaTX, Inc. NCT05743881

Активно (без набиране) Фаза 1

A Study of Idazoxan in Healthy Participants

Healthy

Four-part study of the safety, tolerability and pharmacokinetics of 3 forms of TR-01-XRR, 1 form of TR-01-XRS, and 1 form of TR-01-XR in healthy adults.

Начало: 14.02.2023 Край: 01.12.2027 Възраст: 18–55 г. Лечение

Australia Terran Biosciences Australia Pty Ltd NCT05727189

Активно (без набиране) Фаза 1

Study of ADG206 in Subjects With Advanced/Metastatic Solid Tumors

Advanced/Metastatic Solid Tumors

ADG206 is an activatable prodrug form of a fully human monoclonal antibody (mAb) of the immunoglobulin G1 (IgG1) subclass that specifically targets cluster of differentiation 137 (CD137) (also known as 4-1BB) as a co-stimulatory receptor agonist for the treatment of advanced malignancies.

Начало: 13.02.2023 Край: 30.08.2026 Възраст: от 18 г. Лечение

Australia Adagene Inc NCT05614258

1 … 111 112 113 114 115 … 154